menu

CME: Advanced/Metastatic NSCLC Treatment: Advancements for Patients Without Targetable Activating Mutations

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advanced/Metastatic NSCLC Treatment: Advancements for Patients Without Targetable Activating Mutations

Program Information
Recommended
Advanced/Metastatic NSCLC Treatment: Advancements for Patients Without Targetable Activating Mutations
RestartResume
Through real-world clinical cases, experts reveal how they pick the best treatment approaches based upon unique disease and patient characteristics.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of advanced NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients without targetable activating mutations. Studies evaluating immune checkpoint inhibitors as single agents and in combination with chemotherapy as first-line therapy for patients with advanced NSCLC without targetable activating mutations have been reported. Clinicians need to be familiar with these data and the evolving treatment landscape so they are prepared to optimally select and sequence treatment options for these patients.

    Through real-world clinical cases, the expert panel will evaluate the most recent clinical data and provide evidence-based updates and expert insights on the discussion points. Discussion will include immunotherapy and combination regimens for the initial treatment of patients with advanced NSCLC without targetable activating mutations, and how the experts discerned the best treatment approaches based upon unique disease and patient characteristics.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify first-line therapy options for patients with advanced non–small cell lung cancer without targetable activating mutations based on clinical trial data and guideline recommendations, including platinum-based chemotherapy, and single-agent immune checkpoint inhibitor or in combination with chemotherapy
    • Integrate recommended subsequent chemotherapy and immunotherapy options for the treatment of patients with advanced non–small cell lung cancer without targetable activating mutations
    • Analyze recent clinical trial results supporting the use of chemotherapy and immunotherapy combination regimens for patients with advanced NSCLC without targetable activating mutations
    • Discuss how emerging immunotherapies and chemotherapy combination regimens may be incorporated into future clinical practice
  • Target Audience

    This activity is intended for community-based medical oncologists, thoracic oncologists, pathologists, pulmonologists, physician assistants and other healthcare professionals involved in the treatment of patients with metastatic lung cancer.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Faculty/Presenter

    Reported Financial Relationship

    Karen L. Reckamp, MS, MD

     

    Karen L. Reckamp, MS, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Boehringer Ingelheim; Euclises Pharmaceuticals, Inc; Exelixis, Inc; Guardant Health, Inc; Loxo Oncology; Precision Health; Seattle Genetics, Inc; and Takeda Oncology. Data and Safety Monitoring Committee: Genentech, Inc; and Tesaro, Inc. Research Grant: AbbVie; ACEA; Adaptimmune LLC; Boehringer Ingelheim; Bristol-Myers Squibb Co; Genentech, Inc; Guardant Health, Inc; Janssen Oncology; Loxo Oncology; Seattle Genetics, Inc; Takeda Oncology; Xcovery; and Zeno Pharmaceuticals, Inc.

    Mark A. Socinski, MD

    Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of Speakers' Bureau: Genentech, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Co; and Celgene Corp. Contracted Research: Genentech, Inc; Spectrum Pharmaceuticals, Inc; and Bristol-Myers Squibb Co.

    Helena Yu, MD

    Helena Yu, MD, reported a financial interest/relationship or affiliation in the form of Research funding: Novartis Pharmaceuticals Corp; Lilly USA; AstraZeneca Pharmaceuticals LP; and Daiichi-Sankyo, Inc. Advisory board: AstraZeneca Pharmaceuticals LP.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    The following AXIS planners and managers, Jocelyn Timko, BS, and Michael Brandt, PharmD, FASHP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS, reports her spouse has a financial interest/relationship or affiliation in the form of Common stock: Exelixis.

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AXIS Contact Information
    For information about the certification of this activity, please contact AXIS at info@axismeded.com.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity was supported by educational grants from Celgene Corp; Merck & Co, Inc; and Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/20/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.